Oragenics Inc
OGEN1.260USD
+0.010+0.80%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
27.06MCap. mercado
PérdidaP/E TTM
Más Datos de Oragenics Inc Compañía
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Información de la empresa
Símbolo de cotizaciónOGEN
Nombre de la empresaOragenics Inc
Fecha de salida a bolsaJul 09, 2003
Director ejecutivoMs. Janet Huffman
Número de empleados3
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 09
Dirección1990 Main Street
CiudadSARASOTA
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal34236
Teléfono18132867900
Sitio Webhttps://www.oragenics.com/
Símbolo de cotizaciónOGEN
Fecha de salida a bolsaJul 09, 2003
Director ejecutivoMs. Janet Huffman
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Mr. Tirth T. Patel
Mr. Tirth T. Patel
Vice President
Vice President
--
--
Dr. William (Frank) Peacock, M.D.
Dr. William (Frank) Peacock, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frederick W. Telling, Ph.D.
Dr. Frederick W. Telling, Ph.D.
Independent Director
Independent Director
1.16K
--
Mr. Robert C. Koski
Mr. Robert C. Koski
Independent Director
Independent Director
931.00
--
Mr. Charles L. Pope
Mr. Charles L. Pope
Executive Chairman of the Board
Executive Chairman of the Board
849.00
--
Ms. Janet Huffman
Ms. Janet Huffman
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
500.00
--
Mr. John P. Gandolfo
Mr. John P. Gandolfo
Independent Director
Independent Director
--
--
Dr. James Kelly, M.D.
Dr. James Kelly, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 29 de jul
Actualizado: mar., 29 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Five Narrow Lane LP
9.99%
Cassidy (Bruce A Sr)
1.44%
Geode Capital Management, L.L.C.
0.34%
Two Sigma Investments, LP
0.18%
Telling (Frederick W)
0.14%
Other
87.91%
Accionistas
Accionistas
Proporción
Five Narrow Lane LP
9.99%
Cassidy (Bruce A Sr)
1.44%
Geode Capital Management, L.L.C.
0.34%
Two Sigma Investments, LP
0.18%
Telling (Frederick W)
0.14%
Other
87.91%
Tipos de accionistas
Accionistas
Proporción
Corporation
10.05%
Individual Investor
2.06%
Investment Advisor/Hedge Fund
0.35%
Investment Advisor
0.30%
Hedge Fund
0.21%
Venture Capital
0.10%
Other
86.93%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
51
25.35K
3.08%
-29.87K
2025Q1
54
104.53K
39.81%
+67.24K
2024Q4
61
3.11M
25.46%
+2.05M
2024Q3
59
1.22M
18.08%
+226.05K
2024Q2
58
1.45M
24.58%
+674.78K
2024Q1
57
1.51M
26.60%
+861.00K
2023Q4
59
1.13M
28.10%
+795.74K
2023Q3
58
266.28K
10.68%
+19.84K
2023Q2
53
93.56K
4.68%
-159.82K
2023Q1
59
99.61K
5.08%
-139.03K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Cassidy (Bruce A Sr)
11.82K
1.44%
+3.00
+0.03%
Mar 21, 2025
Geode Capital Management, L.L.C.
2.83K
0.34%
+1.54K
+120.42%
Mar 31, 2025
Two Sigma Investments, LP
1.45K
0.18%
+224.00
+18.35%
Mar 31, 2025
Telling (Frederick W)
1.16K
0.14%
--
--
Mar 21, 2025
Koski (Robert C)
931.00
0.11%
--
--
Mar 21, 2025
Dunton (Alan W)
854.00
0.1%
--
--
Mar 21, 2025
Pope (Charles L)
849.00
0.1%
--
--
Mar 21, 2025
Murphy (Kimberly M)
833.00
0.1%
--
--
Mar 21, 2025
XTX Markets LLC
828.00
0.1%
-470.00
-36.21%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Fecha
Tipo
Relación
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
Dec 23, 2022
Merger
60<1
